A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

NCT05114603 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Shanghai Henlius Biotech